Authorized purpose: MRI image enhancement through noise reduction and sharpening; clinicians retain responsibility for final patient management decisions.
Clinical role
Post-processing image enhancement
Images and patients
MRI · Whole Body
Key limitation
Keep in mind: An image-enhancement aid, not a substitute for clinician decisions; not intended for mobile devices. The listed field strengths define the cleared acquisition scope.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: MRI image enhancement through noise reduction and sharpening; clinicians retain responsibility for final patient management decisions.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Whole Body Input: DICOM MRI of all body parts at 0.25, 0.31, 0.4, 0.55, 0.6, 1.5 and 3.0 T, including images produced by conventional vendor reconstruction or vendor-implemented deep-learning reconstruction.
Who uses it?Intended users: Healthcare professionals, including radiology technologists in imaging centers, clinics and hospitals.
What does the software produce?Output: Enhanced DICOM MR images returned to PACS or the MRI device; adjustable denoising levels 0-8 and sharpness levels 0-5.
What is its most important limitation?Key limitation: An image-enhancement aid, not a substitute for clinician decisions; not intended for mobile devices. The listed field strengths define the cleared acquisition scope.
Clinical takeaway. Clinical role: MRI image enhancement through noise reduction and sharpening; clinicians retain responsibility for final patient management decisions.
Evidence takeaway. Evidence from the reviewed source record: K253775 describes retrospective standalone image-quality validation across adult and pediatric images, body regions, vendors and protocols. Published SwiftMR studies reviewed below are family context, not verified results for version 4.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
MRI image enhancement through noise reduction and sharpening; clinicians retain responsibility for final patient management decisions.
DICOM MRI of all body parts at 0.25, 0.31, 0.4, 0.55, 0.6, 1.5 and 3.0 T, including images produced by conventional vendor reconstruction or vendor-implemented deep-learning reconstruction.
An image-enhancement aid, not a substitute for clinician decisions; not intended for mobile devices. The listed field strengths define the cleared acquisition scope.
K253775 describes retrospective standalone image-quality validation across adult and pediatric images, body regions, vendors and protocols. Published SwiftMR studies reviewed below are family context, not verified results for version 4.
Exact FDA submission
Checked 2026-09-05
Regulatory acceptance thresholds are not reported here as achieved average performance. The public summary does not give a single validation sample total.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K253775 describes retrospective standalone image-quality validation across adult and pediatric images, body regions, vendors and protocols. Published SwiftMR studies reviewed below are family context, not verified results for version 4.
FDA source
Exact FDA submission
Checked 2026-09-05
Regulatory acceptance thresholds are not reported here as achieved average performance. The public summary does not give a single validation sample total.
An exact-release disease-detection sensitivity endpoint was not established in the reviewed enhancement validation.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
An exact-release disease-detection specificity endpoint was not established in the reviewed enhancement validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K253775 standalone MRI enhancement validation
DesignRetrospective standalone image-quality and radiologist evaluation described in the FDA summary
PopulationAdult and pediatric MRI across neuro, musculoskeletal and body applications, scanner vendors, protocols and listed field strengths
Scopeexact submission
Tested versionSwiftMR configuration submitted in K253775
IndependenceSponsor or vendor study
K253775
Includes standard and reduced-acquisition images. No clinical-outcome benefit is inferred from image-quality acceptance criteria.
Leveraging a vendor-neutral deep learning reconstruction algorithm to reduce scan time and enhance image quality in T2-weighted liver MRI
DesignRetrospective single-center image-quality comparison with two radiologist readers
Population86 patients undergoing nonenhanced 3 T liver MRI at Severance Hospital in August 2024
Scopeproduct family
Tested versionSwiftMR; exact software release not established in the reviewed abstract
Samplen=86
Sites1
IndependenceIndependence not established
PMID:42420358 · DOI:10.1038/s41598-026-60802-5
Compared routine two-breath-hold imaging with SwiftMR one- and two-breath-hold imaging. Improved sharpness/SNR did not eliminate the motion tradeoff; no K253775 linkage is asserted.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM MRI of all body parts at 0.25, 0.31, 0.4, 0.55, 0.6, 1.5 and 3.0 T, including images produced by conventional vendor reconstruction or vendor-implemented deep-learning reconstruction.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Automatic background DICOM processing with a client for status and administrative settings; enhanced images transfer to PACS or the MRI device.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Enhanced DICOM MR images returned to PACS or the MRI device; adjustable denoising levels 0-8 and sharpness levels 0-5.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Enhanced DICOM MR images returned to PACS or the MRI device; adjustable denoising levels 0-8 and sharpness levels 0-5.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
AIRS Medical's SwiftMR information security white paper summary states security practices for cloud and on-premises workflows (transport encryption, network access control, application security, identity management, backup, disaster recovery, monitoring) and lists ISO/IEC 27001:2022, GDPR, HIPAA and SOC 2 Type II. Vendor statement about SwiftMR; the full white paper was not read.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
20Fields reviewed
12Source classes checked
3Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
42420358 and 42019274 retained as family contextual studies after abstract review. 38893725 metadata is relevant to TWIST MRA enhancement, but the live PubMed page did not provide readable content and exact-release linkage remains unresolved; no results promoted. The current discovery snapshot contains 3 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, vendor documentation, fda decision summary, vendor product page, peer reviewed literature, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
Reviewed vendor material offers a demo and ROI examples, not a price for the K253775 configuration. A license and implementation quote is needed.
Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission
Per-scanner, per-exam and subscription terms were not established.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "SwiftMR AIRS Medical reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Authorized purpose: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.
Authorized purpose: Vantage Fortian and Orian 1.5T produce diagnostic MR images of the head and body, including labeled noncontrast angiography, for trained technologists and physician interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.